Insights into the use of gadolinium and gadolinium/boron-based agents in imaging-guided neutron capture therapy applications

Annamaria Deagostino, Nicoletta Protti, Diego Alberti, Paolo Boggio, Silva Bortolussi, Saverio Altieri, Simonetta Geninatti Crich

Research output: Contribution to journalReview articlepeer-review

17 Citations (Scopus)

Abstract

Gadolinium neutron capture therapy (Gd-NCT) is currently under development as an alternative approach for cancer therapy. All of the clinical experience to date with NCT is done with 10B, known as boron neutron capture therapy (BNCT), a binary treatment combining neutron irradiation with the delivery of boron-containing compounds to tumors. Currently, the use of Gd for NCT has been getting more attention because of its highest neutron cross-section. Although Gd-NCT was first proposed many years ago, its development has suffered due to lack of appropriate tumor-selective Gd agents. This review aims to highlight the recent advances for the design, synthesis and biological testing of new Gd- and B-Gd-containing compounds with the task of finding the best systems able to improve the NCT clinical outcome.

Original languageEnglish
Pages (from-to)899-917
Number of pages19
JournalFuture Medicinal Chemistry
Volume8
Issue number8
DOIs
Publication statusPublished - May 2016
Externally publishedYes

Keywords

  • boron neutron capture therapy
  • gadolinium neutron capture therapy
  • Gd contrast agents
  • MRI
  • nanosized Gd agents
  • tumor treatment

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Insights into the use of gadolinium and gadolinium/boron-based agents in imaging-guided neutron capture therapy applications'. Together they form a unique fingerprint.

Cite this